Inhaled medicines: past, present, and future

S Anderson, P Atkins, P Bäckman, D Cipolla… - Pharmacological …, 2022 - ASPET
The purpose of this review is to summarize essential pharmacological, pharmaceutical, and
clinical aspects in the field of orally inhaled therapies that may help scientists seeking to …

Advances in soft mist inhalers

V Komalla, CYJ Wong, I Sibum… - Expert Opinion on …, 2023 - Taylor & Francis
ABSTRACT Introduction Soft mist inhalers (SMIs) are propellant-free inhalers that utilize
mechanical power to deliver single or multiple doses of inhalable drug aerosols in the form …

Virtual screening of DrugBank database for hERG blockers using topological Laplacian-assisted AI models

H Feng, GW Wei - Computers in biology and medicine, 2023 - Elsevier
The human ether-a-go-go (hERG) potassium channel (K v 11. 1) plays a critical role in
mediating cardiac action potential. The blockade of this ion channel can potentially lead fatal …

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy

L Calzetta, MG Matera, M Cazzola - Current Opinion in Pharmacology, 2018 - Elsevier
Highlights•Dual bronchodilator therapy has clinical benefits in COPD.•Combining a LABA
with a LAMA synergistically relaxes medium and small airways.•In some approved …

[HTML][HTML] Are anticholinergic medications associated with increased risk of dementia and behavioral and psychological symptoms of dementia? A nationwide 15-year …

YP Liu, WC Chien, CH Chung, HA Chang… - Frontiers in …, 2020 - frontiersin.org
Background/Objective In previous reports, the usage of anticholinergic medications has
been associated with an increased risk of dementia with prolonged usage or with a high …

Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how

L Calzetta, MG Matera, P Rogliani… - Expert Review of …, 2018 - Taylor & Francis
Dual bronchodilation therapy is the cornerstone for the treatment of chronic obstructive
pulmonary disease (COPD)[1]. Combining a long-acting β2 adrenoceptor (β2-AR) agonist …

[HTML][HTML] Inhaled drug therapy-associated adverse reactions in obstructive respiratory diseases: a review of a decade of reporting to the Portuguese Pharmacovigilance …

W Fonseca, C Monteiro, L Taborda-Barata - International Journal of …, 2021 - mdpi.com
Inhaled medication used for treatment of chronic obstructive lung diseases (asthma, chronic
obstructive pulmonary disease-COPD, and Asthma-COPD overlap) may be associated with …

The safety of dual bronchodilation on cardiovascular serious adverse events in COPD

P Rogliani, J Ora, MG Matera, M Cazzola… - Expert Opinion on …, 2018 - Taylor & Francis
ABSTRACT Introduction: Long-acting β2-adrenoceptor (β2-AR) agonists (LABAs) plus long-
acting muscarinic antagonists (LAMAs) is the cornerstone for treating chronic obstructive …

Muscarinic antagonists in early stage clinical development for the treatment of asthma

TE Albertson, JA Chenoweth, JY Adams… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Parasympathetic neurons utilize the neurotransmitter acetylcholine to modulate
and constrict airway smooth muscles at the muscarinic acetylcholine receptor. Inhaled …

One‐year mortality associated with COPD treatment: a comparison of tiotropium and long‐acting beta2‐agonists in three Italian regions: results from the OUTPUL …

U Kirchmayer, S Cascini, N Agabiti… - … and drug safety, 2016 - Wiley Online Library
Purpose Long‐acting bronchodilators, ie beta‐2‐agonists (LABA) and tiotropium are
commonly used in COPD treatment. Choice of a specific agent is based on effectiveness …